News

Servier invests in oncology
Enlarge image

BusinessFrance

Servier invests in oncology

25.09.2012 - French pharma company Les Laboratoires Servier beefs up its oncology pipeline with a deal worth up to US$1.2bn.

In its second deal with US-based Macrogenics, the major French pharma company has entered into an option agreement to develop and commercialise three Macrogenics products. Under the terms of the agreement, Macrogenics receives US$20m upfront, as well as US$1.1bn in milestone payments and double digit royalties. It will use its Dual-Affinity Re-Targeting (DART) platform to develop up to three proteins that target un-diagnosed solid and liquid tumours. It retains full development and commercialisation rights to the programmes in the US, Canada, Mexico, Japan, Korea and India, while Servier has the option to obtain an exclusive license covering the rest of the world for each of the programmes.

„We believe bi-specific antibodies are an important new frontier in medicine. Macrogenics is well positioned to be a leader in this exciting area, given the robustness and versatility of their DART platform”, said Stéphane Depil, in charge of Oncology Research & Development at Servier. His company partnered with Macrogenics for the first time in late 2011 on MGA271, a monoclonal antibody that recognises B7-H3, a novel member of the B7 family of immune regulators. With Pfizer and Boehringer Ingelheim, two other major pharma companies are already using the DART platform since at least October 2010.

These deals mark a remarkable comeback for Macrogenics: only two years ago the company spiked ist lead product, type 1 diabetes drug teplizumab, partnered to Eli Lilly & Co., after disappointing Phase III study results

© eurobiotechnews.eu/bk

http://www.european-biotechnology-news.com/news/news/2012-03/servier-invests-in-oncology.html

PoliticsSwitzerland

23.10.2014 Just one day before its planned initial listing, Swiss Molecular Partners has cancelled its IPO. The reason: "unfavourable market conditions".

PoliticsEU

23.10.2014 Jean-Claude Juncker can breathe a sigh of relief as MEPs voted “yes” by a large majority to his team of European Union Commissioners. Previous to the vote, Juncker had shifted the EMA back to the health commissioner in response to protests.

FinancingFrance

21.10.2014 Yet another European company is looking for money on the US stock exchange – French DBV Technologies SA is all set up for its secondary listing on NASDAQ. The French biotech company hopes to rake in US$98m for its peanut allergy patches.

FinancingDenmark

18.10.2014 After raising US$220.5m (€172m) with its IPO, fast Forward Pharma’s lucky streak hits an obstacle on the road to success with shares falling 17% on its first day of trading.

M&AUKItaly

17.10.2014 Abandoned at the altar: Abbvie has dropped plans to acquire UK’s Shire following new US tax rules. This puts a stop to one of the biggest pharma mergers planned this year.

FinancingUKBelgium

15.10.2014 Bicycle Therapeutics wins €25m backing by major pharma venture capitalists for the development of a new class of oncology drugs.

FinancingGermanySwitzerlandNetherlands

13.10.2014 Biotechnology IPOs are back in fashion – German Probiodrug AG wants to raise €32m with its IPO, whilst Swiss Molecular Partners AG hopes the launch of its IPO will gain a revenue of €145m.

BusinessIreland

10.10.2014 Actavis has announced plans to merge with American pharma company Durata - a move that will strengthen their infectious diseases portfolio.

RegulationEU

07.10.2014 In an unprecedented move, the European Medicines Agency has approved a system allowing the future analysis of clinical trial data.

FinanceNetherlandsEU

06.10.2014 Another fund from the Netherlands has raised €92m in its first close and will invest the money in companies developing innovative therapeutics, medical devices and diagnostics.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • 4SC0.97 EUR0.00%
  • ACTELION112.40 CHF0.00%
  • ADDEX3.30 CHF0.00%

FLOP

  • CYTOTOOLS31.45 EUR-0.47%
  • 4SC0.97 EUR0.00%
  • ACTELION112.40 CHF0.00%

TOP

  • BIOFRONTERA2.90 EUR31.8%
  • VITA 344.32 EUR7.2%
  • BB BIOTECH157.70 EUR6.1%

FLOP

  • PAION2.24 EUR-27.7%
  • CYTOS0.16 CHF-23.8%
  • MAGFORCE5.90 EUR-16.9%

TOP

  • SANTHERA85.50 CHF2288.3%
  • CO.DON2.75 EUR183.5%
  • PAION2.24 EUR143.5%

FLOP

  • CYTOS0.16 CHF-95.9%
  • 4SC0.97 EUR-44.3%
  • THERAMETRICS0.08 CHF-42.9%

No liability assumed, Date: 25.10.2014